Featured Research

from universities, journals, and other organizations

Researchers test drug combinations to prevent graft vs. host disease

Date:
June 26, 2012
Source:
Moffitt Cancer Center
Summary:
Researchers have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

The study randomized 74 patients, ages 16 to 70, to receive either SIR/TAC or MTX/TAC. Patients were stratified by donor relation (siblings or matched, unrelated individuals) and age.

Their study was published in a recent issue of Haematologica, the journal of the European Hematology Association.

"Graft vs. host disease poses major health problems for patients who have received hematopoietic cell transplants and threatens the long-term success of their transplant," said Joseph Pidala, M.D., M.S., a medical oncologist and study principal investigator. "Existing pharmacologic strategies do not adequately prevent acute graft vs. host disease following allogeneic hematopoietic (blood) cell transplantation, and effective acute GVHD prevention is an important clinical goal necessary to ensure the long-term success of transplantation."

According to the authors, their study design mandated at least one year of sirolimus therapy in order to both limit the risk from chronic GVHD development and to promote the patients' immune tolerance based on the "reconstitution" of the patients' immune cells, called regulatory T cells, or "Tregs."

"Our hypothesis was that SIR-based immune suppression would suppress alloreactive T cells, support the recovery of the immune system's Tregs, and more effectively prevent GVHD," explained Pidala.

Results showed that on days 30 and 90 post transplantation, SIR/TAC-treated patients had "a significantly greater proportion of regulatory T cells among the CD 4 immune cells in their peripheral blood" and their regulatory Tregs were "functional."

The authors suggested that the "net benefit" observed in Treg reconstitution with SIR/TAC-treated patients was likely due to both the suppression of immune systems' non-Treg CD4 T cells by sirolimus, as well as the lower tacrolimus exposure for these patients as compared to patients on the MTX/TAC arm of the study.

The study was carried out by Moffitt researchers from several departments, programs and centers, including Immunology; Blood & Marrow Transplant; Biostatistics; Health Outcomes & Behavior; and Oncologic Sciences, College of Medicine, University of South Florida.

Support came from the American Cancer Society (MRSG-11-149-01-LIB), National Cancer Institute/NIH (R01 CA132197) and the Moffitt Cancer Center Foundation.


Story Source:

The above story is based on materials provided by Moffitt Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Pidala, J. Kim, H. Jim, M. A. Kharfan-Dabaja, T. Nishihori, H. Fernandez, M. Tomblyn, L. Perez, J. Perkins, M. Xu, W. Janssen, A. Veerapathran, B. Betts, F. L. Locke, E. Ayala, T. Field, L. Ochoa-Bayona, M. Alsina, C. Anasetti. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica, 2012; DOI: 10.3324/haematol.2012.067140

Cite This Page:

Moffitt Cancer Center. "Researchers test drug combinations to prevent graft vs. host disease." ScienceDaily. ScienceDaily, 26 June 2012. <www.sciencedaily.com/releases/2012/06/120626113926.htm>.
Moffitt Cancer Center. (2012, June 26). Researchers test drug combinations to prevent graft vs. host disease. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2012/06/120626113926.htm
Moffitt Cancer Center. "Researchers test drug combinations to prevent graft vs. host disease." ScienceDaily. www.sciencedaily.com/releases/2012/06/120626113926.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins